Your Messages Inbox
Your Article Summary
See Latest ArticlesACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate alone
Chugai Pharmaceutical Co., 11/02/09
Two–year data from the LITHE study, being presented at the American College of Rheumatology, show that, with long–term use, patients with rheumatoid arthritis treated with ACTEMRA plus methotrexate suffered 81% less damage to their joints compared to those treated with MTX, the current standard therapy, alone1. For patients, this means that their joint damage is significantly reduced, and that they can therefore continue to enjoy their lives without the evolving disability usually associated with the disease.
Today in Medical Devices/Products...keeping you current
Receive free subspecialty "5-minute updates" via email
Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/25/09
Huntington Hill Installs Toshiba Aquilion Premium CT
Imaging Economics, 11/25/09
Baytubes carbon nanotubes in marine coatings help reduce frictional resistance
BayNews International, 11/24/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09
Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09
Article Search
Sponsor